Anti-TGF-beta monoclonal antibody 2G7Alternative Names: Anti-TGF-beta 2G7; Anti-TGF-beta antibody 2G7; Anti-transforming growth factor-beta monoclonal antibody 2G7
Latest Information Update: 15 Aug 2002
At a glance
- Originator Genentech
- Developer Genentech; Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer